MAIA Biotechnology (MAIA)

• Market cap: $45.9M
• 1 day: 0.65%
• 5 days: 5.44%
• 1 month: -7.19%
• 3 months: -22.50%
• 6 months: -38.49%
• Year to date: -25.84%
• 1 year: -21.72%
• 5 years: -65.25%
• 10 years: -65.25%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

Employees: 13

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

200% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 2

50% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 4

12% more funds holding

Funds holding: 17 [Q3] → 19 (+2) [Q4]

0.85% less ownership

Funds ownership: 6.14% [Q3] → 5.29% (-0.85%) [Q4]

34% less capital invested

Capital invested by funds: $4.15M [Q3] → $2.74M (-$1.41M) [Q4]